Literature DB >> 26602539

Myositis-specific autoantibodies: an important tool to support diagnosis of myositis.

Z Betteridge1, N McHugh1,2.   

Abstract

The idiopathic inflammatory myopathies are characterized by muscle weakness, skin disease and internal organ involvement. Autoimmunity is known to have a role in myositis pathogenesis, and myositis-specific autoantibodies, targeting important intracellular proteins, are regarded as key biomarkers aiding in the diagnosis of patients. In recent years, a number of novel myositis autoantibodies including anti-TIF1, anti-NXP2, anti-MDA5, anti-SAE, anti-HMGCR and anti-cN1A have been identified in both adult and juvenile patients. These autoantibodies correlate with distinct clinical manifestations and importantly are found in inclusion body, statin-induced, clinically amyopathic and juvenile groups of myositis patients, previously believed to be mainly autoantibody negative. In this review, we will describe the main myositis-specific and myositis-associated autoantibodies and their frequencies and clinical associations across different ages and ethnic groups. We will also discuss preliminary studies investigating correlations between specific myositis autoantibody titres and clinical markers of disease course, collectively demonstrating the utility of myositis autoantibodies as both diagnostic and prognostic markers of disease.
© 2015 The Association for the Publication of the Journal of Internal Medicine.

Entities:  

Keywords:  Autoantibodies; Autoimmunity; Dermatomyositis; Myositis; Polymyositis

Mesh:

Substances:

Year:  2015        PMID: 26602539     DOI: 10.1111/joim.12451

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  93 in total

Review 1.  Update on outcome assessment in myositis.

Authors:  Lisa G Rider; Rohit Aggarwal; Pedro M Machado; Jean-Yves Hogrel; Ann M Reed; Lisa Christopher-Stine; Nicolino Ruperto
Journal:  Nat Rev Rheumatol       Date:  2018-04-12       Impact factor: 20.543

Review 2.  Classification of myositis.

Authors:  Ingrid E Lundberg; Marianne de Visser; Victoria P Werth
Journal:  Nat Rev Rheumatol       Date:  2018-04-12       Impact factor: 20.543

3.  Antisynthetase syndrome in pregnancy: A case and review of the literature.

Authors:  Lauren J Green; Lorraine O'Neill; Charlotte J Frise
Journal:  Obstet Med       Date:  2018-11-08

4.  Cutaneous and Systemic Findings Associated With Nuclear Matrix Protein 2 Antibodies in Adult Dermatomyositis Patients.

Authors:  Anna Rogers; Lorinda Chung; Shufeng Li; Livia Casciola-Rosen; David F Fiorentino
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-11-02       Impact factor: 4.794

5.  Antibodies to small ubiquitin-like modifier activating enzyme are associated with a diagnosis of dermatomyositis: results from an unselected cohort.

Authors:  Lisa K Peterson; Troy D Jaskowski; Sonia L La'ulu; Anne E Tebo
Journal:  Immunol Res       Date:  2018-06       Impact factor: 2.829

6.  Utilization patterns and performance of commercial myositis autoantibody panels in routine clinical practice.

Authors:  P C Gandiga; J Zhang; S Sangani; P Thomas; V P Werth; M D George
Journal:  Br J Dermatol       Date:  2019-08-18       Impact factor: 9.302

Review 7.  [Inflammatory myopathies].

Authors:  Britta Maurer
Journal:  Z Rheumatol       Date:  2017-02       Impact factor: 1.372

Review 8.  Calcinosis and malignancy are rare in Chinese adult patients with myositis and nuclear matrix protein 2 antibodies identified by an unlabeled immunoprecipitation assay.

Authors:  Li Wang; Li Huang; Yang Yang; Huan Chen; Yanjuan Liu; Ke Liu; Meidong Liu; Yizhi Xiao; Hui Luo; Xiaoxia Zuo; Yisha Li; Xianzhong Xiao; Huali Zhang
Journal:  Clin Rheumatol       Date:  2018-07-23       Impact factor: 2.980

Review 9.  Potential Pathogenic Role of Anti-Signal Recognition Protein and Anti-3-hydroxy-3-methylglutaryl-CoA Reductase Antibodies in Immune-Mediated Necrotizing Myopathies.

Authors:  Leandro Ladislau; Louiza Arouche-Delaperche; Yves Allenbach; Olivier Benveniste
Journal:  Curr Rheumatol Rep       Date:  2018-08-03       Impact factor: 4.592

Review 10.  Selected aspects of the current management of myositis.

Authors:  James Lilleker; Sean Murphy; Robert Cooper
Journal:  Ther Adv Musculoskelet Dis       Date:  2016-06-19       Impact factor: 5.346

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.